CO6190603A2 - Acido 7-(2-metilpiridin-3-il carbomoil)-4a-benzil-2-(trifluorometil)-1,2,3,4,4a, 9, 10, 10a-octahidro fenantren-2-il-2-fosfonico como moduladores del receptor glucocorticoide - Google Patents

Acido 7-(2-metilpiridin-3-il carbomoil)-4a-benzil-2-(trifluorometil)-1,2,3,4,4a, 9, 10, 10a-octahidro fenantren-2-il-2-fosfonico como moduladores del receptor glucocorticoide

Info

Publication number
CO6190603A2
CO6190603A2 CO09079796A CO09079796A CO6190603A2 CO 6190603 A2 CO6190603 A2 CO 6190603A2 CO 09079796 A CO09079796 A CO 09079796A CO 09079796 A CO09079796 A CO 09079796A CO 6190603 A2 CO6190603 A2 CO 6190603A2
Authority
CO
Colombia
Prior art keywords
compound
glucocorticoid receptor
carbomoil
methylpiridin
fenantren
Prior art date
Application number
CO09079796A
Other languages
English (en)
Spanish (es)
Inventor
Rajesh Venkateswaran Devraj
Xiao Hu
Kevin D Jerome
Mark Gerrd Obukowicz
Ronald Keith Webber
Paul V Rucker
Lisa Olson
Gary A Crescenzo
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CO6190603A2 publication Critical patent/CO6190603A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
CO09079796A 2007-02-02 2009-07-31 Acido 7-(2-metilpiridin-3-il carbomoil)-4a-benzil-2-(trifluorometil)-1,2,3,4,4a, 9, 10, 10a-octahidro fenantren-2-il-2-fosfonico como moduladores del receptor glucocorticoide CO6190603A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88798107P 2007-02-02 2007-02-02

Publications (1)

Publication Number Publication Date
CO6190603A2 true CO6190603A2 (es) 2010-08-19

Family

ID=39315208

Family Applications (2)

Application Number Title Priority Date Filing Date
CO09079796A CO6190603A2 (es) 2007-02-02 2009-07-31 Acido 7-(2-metilpiridin-3-il carbomoil)-4a-benzil-2-(trifluorometil)-1,2,3,4,4a, 9, 10, 10a-octahidro fenantren-2-il-2-fosfonico como moduladores del receptor glucocorticoide
CO09079789A CO6220937A2 (es) 2007-02-02 2009-07-31 Compuestos triciclicos composiciones y procedimientos

Family Applications After (1)

Application Number Title Priority Date Filing Date
CO09079789A CO6220937A2 (es) 2007-02-02 2009-07-31 Compuestos triciclicos composiciones y procedimientos

Country Status (42)

Country Link
US (7) US7547714B2 (https=)
EP (1) EP2114970B1 (https=)
JP (1) JP4599462B2 (https=)
KR (2) KR101107949B1 (https=)
CN (2) CN101616925B (https=)
AP (1) AP2455A (https=)
AR (2) AR065135A1 (https=)
AT (1) ATE518872T1 (https=)
AU (1) AU2008211613B2 (https=)
BR (1) BRPI0808634A2 (https=)
CA (1) CA2676670C (https=)
CL (2) CL2008000330A1 (https=)
CO (2) CO6190603A2 (https=)
CR (2) CR10948A (https=)
CU (2) CU23824A3 (https=)
CY (2) CY1110962T1 (https=)
DK (1) DK2114970T3 (https=)
DO (1) DOP2009000190A (https=)
EA (1) EA016494B1 (https=)
EC (2) ECSP099553A (https=)
ES (2) ES2368286T3 (https=)
GE (2) GEP20125404B (https=)
GT (2) GT200900210A (https=)
HN (2) HN2008000178A (https=)
HR (1) HRP20110702T1 (https=)
IL (1) IL199972A (https=)
MA (2) MA31158B1 (https=)
MX (1) MX2009008284A (https=)
MY (3) MY153057A (https=)
NI (2) NI200900149A (https=)
NZ (1) NZ578638A (https=)
PE (2) PE20081736A1 (https=)
PL (1) PL2114970T3 (https=)
PT (2) PT2114970E (https=)
RS (2) RS51970B (https=)
SI (1) SI2114970T1 (https=)
SV (2) SV2009003346A (https=)
TN (1) TN2009000324A1 (https=)
TW (2) TWI347842B (https=)
UA (2) UA94639C2 (https=)
WO (1) WO2008093227A1 (https=)
ZA (2) ZA200906064B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
HRP20110702T1 (hr) * 2007-02-02 2011-10-31 Pfizer Products Inc. Triciklički spojevi i njihova uporaba kao modulatora glukokortikoidnih receptora
ES2527137T3 (es) 2008-07-28 2015-01-21 Pfizer Inc. Compuestos de fenantrenona, composiciones y procedimientos
WO2010059894A1 (en) * 2008-11-21 2010-05-27 Bridge Pharma, Inc. Ocular formulations of norketotifen
US20100135983A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100137787A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Delivery devices for modulating inflammation
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136096A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100137246A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100136095A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
AU2011251622A1 (en) 2010-05-10 2012-12-20 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
KR20130106378A (ko) * 2010-08-27 2013-09-27 코어셉트 쎄라퓨틱스, 잉크. 피리딜-아민 융합된 아자데칼린 조절제
WO2012125797A1 (en) * 2011-03-15 2012-09-20 Abbott Laboratories Nuclear hormone receptor modulators
US8545904B1 (en) 2012-06-05 2013-10-01 Liquid Innovators, LLC Topical composition containing Carapa (andiroba) oil for psoriasis and other related dermatological disorders
US9227901B2 (en) 2012-07-05 2016-01-05 Abbvie Inc. Process for preparing bicyclic amine derivatives
TW201422590A (zh) 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
WO2014094357A1 (en) 2012-12-21 2014-06-26 Abbvie Inc. Heterocyclic nuclear hormone receptor modulators
MX389718B (es) 2014-05-16 2025-03-20 Olaplex Inc Formulaciones y metodos de tratamiento con queratina.
EP3848028B9 (en) 2014-10-20 2024-10-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
CN104591988A (zh) * 2014-12-29 2015-05-06 甘肃省化工研究院 6-溴-2-萘满酮的合成方法
WO2016149756A1 (en) 2015-03-23 2016-09-29 The University Of Melbourne Treatment of respiratory diseases
MX385698B (es) 2016-04-07 2025-03-18 Oyster Point Pharma Inc Uso de un compuesto que comprende un grupo pirrolidinilo y pirimidinilo para tratar enfermedades oculares
JP7614646B2 (ja) 2018-11-07 2025-01-16 ティアンリ バイオテック プロプライエタリ リミテッド 呼吸器疾患の処置のための化合物及び組成物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2576025B1 (fr) 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
FR2600450B1 (fr) * 1986-06-19 1988-08-26 Pechiney Aluminium Procede de marquage individuel des anodes precuites pour la production electrolytique d'aluminium
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
IL122740A (en) 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
MXPA01011018A (es) * 1999-04-30 2002-05-06 Pfizer Prod Inc Moduladores del receptor glucocorticoide.
WO2001005229A1 (en) 1999-07-15 2001-01-25 The General Hospital Corporation Non-defective epstein-barr viral vector
IL146057A (en) * 2000-10-27 2007-09-20 Pfizer Prod Inc A process for the preparation of modulators of a non-steroidal glucocorticoid receptor
ES2262612T3 (es) * 2000-10-28 2006-12-01 Pfizer Products Inc. Moduladpres del receptor de glucocorticoides.
ES2246292T3 (es) 2000-10-30 2006-02-16 Pfizer Products Inc. Moduladores de receptor glucocorticoide.
US6462661B2 (en) * 2000-11-20 2002-10-08 Seagate Technology Llc RF ID tag attachment to a disc drive
CA2450748A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
IL160649A0 (en) 2001-08-31 2004-07-25 Corcept Therapeutics Inc Methods for inhibiting cognitive deterioration in adults with down syndrome
WO2003029217A2 (en) 2001-09-27 2003-04-10 Universite De Liege Pyridinic sulfonamide derivatives, method of production and use thereof
DE10164366C1 (de) * 2001-12-28 2003-06-05 Rehau Ag & Co Permanentkathode
DE60320940D1 (de) 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
CN1665515A (zh) 2002-07-02 2005-09-07 科塞普特治疗公司 治疗与干扰素α治疗相关的精神病的方法
JP4503436B2 (ja) 2002-07-08 2010-07-14 ファイザー・プロダクツ・インク 糖質コルチコイド受容体のモジュレーター
JP2006508951A (ja) 2002-11-05 2006-03-16 コーセプト セラピューティクス， インコーポレイテッド 片頭痛を処置するための方法
EP1599208A4 (en) 2003-02-04 2007-09-12 Corcept Therapeutics Inc ANTIGLUCOCORTICOIDES FOR THE TREATMENT OF POSTPARTAL PSYCHOSIS
US20050080061A1 (en) 2003-07-23 2005-04-14 Corcept Therapeutics, Inc. Antiglucocorticoid therapy for the prevention of neurological damage in premature infants
US8097606B2 (en) 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
TW200512181A (en) 2003-09-26 2005-04-01 Tanabe Seiyaku Co Amide-type carboxamide derivatives
WO2005047524A2 (en) * 2003-11-10 2005-05-26 The Scripps Research Institute Compositions and methods for inducing cell dedifferentiation
CA2545020A1 (en) * 2003-11-13 2005-05-26 Pfizer Products Inc. Octahydrophenanthrene hydrazinde derivatives useful as glucocorticoid receptor modulators
TWI370129B (en) 2005-02-14 2012-08-11 Msd Oss Bv Non steroidal glucocorticoid receptor modulators
JP2009535430A (ja) 2006-05-02 2009-10-01 コーセプト セラピューティクス， インコーポレイテッド Ｉｌ−２を摂取している患者における抑うつを処置するためのグルココルチコイドレセプターｉｉアンタゴニストの使用
EP2114888B1 (en) * 2007-02-02 2010-11-10 Pfizer Products Inc. Tricyclic compounds and their use as glucocorticoid receptor modulators
HRP20110702T1 (hr) * 2007-02-02 2011-10-31 Pfizer Products Inc. Triciklički spojevi i njihova uporaba kao modulatora glukokortikoidnih receptora

Also Published As

Publication number Publication date
NI200900149A (es) 2010-02-15
US7547714B2 (en) 2009-06-16
IL199972A (en) 2013-09-30
IL199972A0 (en) 2010-04-15
PT2114970E (pt) 2011-09-22
CU20090132A7 (es) 2011-10-14
RS51970B (sr) 2012-02-29
HN2008000178A (es) 2011-02-25
NI200900148A (es) 2010-02-15
ECSP099552A (es) 2009-08-28
EP2114970A1 (en) 2009-11-11
PT2114888E (pt) 2011-01-04
CU23848B1 (es) 2012-10-15
TWI373466B (en) 2012-10-01
UA95332C2 (uk) 2011-07-25
US20140316139A1 (en) 2014-10-23
CL2008000330A1 (es) 2008-08-08
MY153057A (en) 2014-12-31
KR101114682B1 (ko) 2012-03-14
US20090281148A1 (en) 2009-11-12
WO2008093227A1 (en) 2008-08-07
CA2676670A1 (en) 2008-08-07
DK2114970T3 (da) 2011-09-19
GT200900209A (es) 2010-07-22
SI2114970T1 (sl) 2011-11-30
CL2008000329A1 (es) 2008-08-08
CR10948A (es) 2009-08-07
ES2353822T3 (es) 2011-03-07
CO6220937A2 (es) 2010-11-19
HRP20110702T1 (hr) 2011-10-31
JP4599462B2 (ja) 2010-12-15
HK1135108A1 (en) 2010-05-28
RS51646B (sr) 2011-10-31
AR065135A1 (es) 2009-05-20
KR101107949B1 (ko) 2012-02-08
US8901310B2 (en) 2014-12-02
CN101616925B (zh) 2012-05-23
MY146087A (en) 2012-06-29
CU20090133A7 (es) 2011-10-31
SV2009003346A (es) 2010-04-13
US20120088802A9 (en) 2012-04-12
ECSP099553A (es) 2009-08-28
CN101616896B (zh) 2012-07-04
BRPI0808634A2 (pt) 2014-08-05
MY148780A (en) 2013-05-31
ATE518872T1 (de) 2011-08-15
AU2008211613B2 (en) 2013-05-23
CY1110962T1 (el) 2015-06-11
CR10949A (es) 2009-08-07
TN2009000324A1 (fr) 2010-12-31
AP2455A (en) 2012-08-31
US20080312294A1 (en) 2008-12-18
US7598231B2 (en) 2009-10-06
PE20081736A1 (es) 2008-11-28
US8158660B2 (en) 2012-04-17
US20100286214A1 (en) 2010-11-11
EP2114970B1 (en) 2011-08-03
MA31158B1 (fr) 2010-02-01
PE20090113A1 (es) 2009-02-13
US8445520B2 (en) 2013-05-21
UA94639C2 (ru) 2011-05-25
MA31117B1 (fr) 2010-01-04
ZA200906060B (en) 2010-05-26
CN101616925A (zh) 2009-12-30
ES2368286T3 (es) 2011-11-16
DOP2009000190A (es) 2009-08-31
CN101616896A (zh) 2009-12-30
GT200900210A (es) 2010-04-05
US7786097B2 (en) 2010-08-31
TW200838514A (en) 2008-10-01
HN2008000179A (es) 2010-06-09
TWI347842B (en) 2011-09-01
GEP20125404B (en) 2012-02-27
CA2676670C (en) 2012-03-13
JP2010517990A (ja) 2010-05-27
TW200846325A (en) 2008-12-01
KR20090107080A (ko) 2009-10-12
AR065134A1 (es) 2009-05-20
SV2009003349A (es) 2010-04-13
CY1111758T1 (el) 2015-10-07
EA200970666A1 (ru) 2010-02-26
US20080188443A1 (en) 2008-08-07
NZ578638A (en) 2010-12-24
PL2114970T3 (pl) 2011-11-30
US20140142316A1 (en) 2014-05-22
US20120095062A1 (en) 2012-04-19
EA016494B1 (ru) 2012-05-30
GEP20125426B (en) 2012-03-26
AU2008211613A1 (en) 2008-08-07
ZA200906064B (en) 2010-05-26
AP2009004942A0 (en) 2009-08-31
KR20090108115A (ko) 2009-10-14
MX2009008284A (es) 2009-08-12
CU23824A3 (es) 2011-10-31

Similar Documents

Publication Publication Date Title
CO6190603A2 (es) Acido 7-(2-metilpiridin-3-il carbomoil)-4a-benzil-2-(trifluorometil)-1,2,3,4,4a, 9, 10, 10a-octahidro fenantren-2-il-2-fosfonico como moduladores del receptor glucocorticoide
PE20131047A1 (es) Compuestos heterociclicos moduladores del acido urico
NI201300002A (es) Derivados de tetrahidro-pirido-pirimidina
CL2012000181A1 (es) Composicion antimicrobiana para extender la vida util del agua, alimentos o ingredientes de alimentos que comprende 1% a 99% en peso de ácidos orgánicos en solucion acuosa, 0-20% de peso de terpenos y 0-5% de surfactantes; método para extender la vida util del agua, alimentos o ingredientes de alimentos.
TN2009000199A1 (en) Heteromonocyclic compound and use thereof
CY1118189T1 (el) Εμπλουτισμος αφαλατωμενου και γλυκου νερου με χορηγηση ενος διαλυματος ανθρακικου ασβεστιου σε μαλακο νερο
BR112013029538A2 (pt) catalisador de reação de fenton produzido usando substância redutora orgânica como matéria-prima
CL2012000588A1 (es) Método de tratamiento de semilla que comprende poner en contacto la semilla con una composición que comprende una mezcla compleja agrícolamente aceptable de material orgánico disuelto caracterizado por material orgánico natural que es parcialmente humificado.
UA113981C2 (xx) Офтальмологічний розчин, що містить диквафасол
EA201100896A1 (ru) Композиция, предназначенная для всасывания никотина из ротовой полости с целью прекратить курение
EA201270216A1 (ru) Фармацевтический состав
AR089228A1 (es) Rendimiento dirigido de las composiciones de hipohalito, sus metodos y sistemas
BRPI0922220A8 (pt) Uso de compostos antibacterianos, composição farmacêutica e combinação compreendendo os mesmos
AR065963A1 (es) Solucion acuosa de peroxido de hidrogeno, proceso para su preparacion y su uso
PE20120648A1 (es) Compuestos de 4-isopropilfenilglucitol como inhibidores de sglt1
AR077691A1 (es) Tratamiento de plantas ornamentales
BR112013010918A2 (pt) sal de alumínio contendo elevada percentagem de al30
BR112015022765A2 (pt) composição biocida e processo de tratamento da água ou de superfícies em contato com água
CO2022011388A2 (es) Inhibidores heterocíclicos de pad4
BR112012017994A2 (pt) composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio
UA107562C2 (uk) Спосіб лікування псоріазу
MX2015016057A (es) Solucion estabilizada de acido hipocloroso y uso de la misma.
PE20120643A1 (es) PROCESO PARA LA OBTENCION DEL ACIDO (S)-2-METOXI-3-{4-[2-(5-METIL-2-FENIL-OXAZOL-4-IL)-ETOXI]-BENZO[b]TIOFEN-7-IL}-PROPIONICO EN PRESENCIA DE UN CATALIZADOR DE IRIDIO
PE20120915A1 (es) Octasacaridos n-acilos activadores de los receptores de los fgf y su preparacion
PE20140811A1 (es) Precipitacion de zinc de la solucion

Legal Events

Date Code Title Description
FG Application granted